Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 1
1988 1
1989 1
1990 1
1991 1
1992 1
1997 1
1999 3
2000 1
2002 1
2003 1
2004 2
2005 1
2006 1
2008 1
2010 1
2012 1
2016 1
2020 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.
Sacchi S, Marcheselli R, Bari A, Buda G, Molinari AL, Baldini L, Vallisa D, Cesaretti M, Musto P, Ronconi S, Specchia G, Silvestris F, Guardigni L, Ferrari A, Chiapella A, Carella AM, Santoro A, Di Raimondo F, Marcheselli L, Pozzi S. Sacchi S, et al. Among authors: guardigni l. Haematologica. 2016 May;101(5):e196-9. doi: 10.3324/haematol.2015.139329. Epub 2016 Feb 8. Haematologica. 2016. PMID: 26858355 Free PMC article. Clinical Trial. No abstract available.
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network. Cavo M, et al. Blood. 2012 Jul 5;120(1):9-19. doi: 10.1182/blood-2012-02-408898. Epub 2012 Apr 12. Blood. 2012. PMID: 22498745 Free article. Clinical Trial.
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M; GIMEMA Italian Myeloma Network. Cavo M, et al. Lancet. 2010 Dec 18;376(9758):2075-85. doi: 10.1016/S0140-6736(10)61424-9. Epub 2010 Dec 9. Lancet. 2010. PMID: 21146205 Clinical Trial.
Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients.
Zinzani PL, Storti S, Zaccaria A, Moretti L, Magagnoli M, Pavone E, Gentilini P, Guardigni L, Gobbi M, Fattori PP, Falini B, Lauta VM, Bendandi M, Gherlinzoni F, De Renzo A, Zaja F, Mazza P, Volpe E, Bocchia M, Aitini E, Tabanelli M, Leone G, Tura S. Zinzani PL, et al. Among authors: guardigni l. Blood. 1999 Jul 1;94(1):33-8. Blood. 1999. PMID: 10381495 Free article. Clinical Trial.
Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients.
Zinzani PL, Gherlinzoni F, Storti S, Zaccaria A, Pavone E, Moretti L, Gentilini P, Guardigni L, De Renzo A, Fattori PP, Falini B, Lauta VM, Mannina D, Zaja F, Mazza P, Volpe E, Lauria F, Aitini E, Ciccone F, Tani M, Stefoni V, Alinari L, Baccarani M, Tura S. Zinzani PL, et al. Among authors: guardigni l. Ann Oncol. 2002 Sep;13(9):1364-9. doi: 10.1093/annonc/mdf208. Ann Oncol. 2002. PMID: 12196361 Free article. Clinical Trial.
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Tacchetti P, Pantani L, Patriarca F, Petrucci MT, Zamagni E, Dozza L, Galli M, Di Raimondo F, Crippa C, Boccadoro M, Barbato S, Tosi P, Narni F, Montefusco V, Testoni N, Spadano A, Terragna C, Pescosta N, Marzocchi G, Cellini C, Galieni P, Ronconi S, Gobbi M, Catalano L, Lazzaro A, De Sabbata G, Cangialosi C, Ciambelli F, Musto P, Elice F, Cavo M; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto Italian Myeloma Network). Tacchetti P, et al. Lancet Haematol. 2020 Dec;7(12):e861-e873. doi: 10.1016/S2352-3026(20)30323-9. Lancet Haematol. 2020. PMID: 33242443 Clinical Trial.
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, Storti S, Lauta VM, Guardigni L, Gentilini P, Tucci A, Molinari AL, Gobbi M, Falini B, Fattori PP, Ciccone F, Alinari L, Martelli M, Pileri S, Tura S, Baccarani M. Zinzani PL, et al. Among authors: guardigni l. J Clin Oncol. 2004 Jul 1;22(13):2654-61. doi: 10.1200/JCO.2004.07.170. Epub 2004 May 24. J Clin Oncol. 2004. PMID: 15159414 Clinical Trial.
[The immunological status in viral hepatitis].
Iosa G, Riceputi G, Turci F, Biagioli R, Guardigni L, Cenciotti L, Pretolani E. Iosa G, et al. Among authors: guardigni l. Minerva Med. 1980 May 26;71(21):1501-5. Minerva Med. 1980. PMID: 6770309 Italian. No abstract available.
Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma.
Zinzani PL, Magagnoli M, Moretti L, De Renzo A, Battista R, Zaccaria A, Guardigni L, Mazza P, Marra R, Ronconi F, Lauta VM, Bendandi M, Gherlinzoni F, Gentilini P, Ciccone F, Cellini C, Stefoni V, Ricciuti F, Gobbi M, Tura S. Zinzani PL, et al. Among authors: guardigni l. J Clin Oncol. 2000 Feb;18(4):773-9. doi: 10.1200/JCO.2000.18.4.773. J Clin Oncol. 2000. PMID: 10673518 Clinical Trial.
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Zinzani PL, Tani M, Pulsoni A, Gobbi M, Perotti A, De Luca S, Fabbri A, Zaccaria A, Voso MT, Fattori P, Guardigni L, Ronconi S, Cabras MG, Rigacci L, De Renzo A, Marchi E, Stefoni V, Fina M, Pellegrini C, Musuraca G, Derenzini E, Pileri S, Fanti S, Piccaluga PP, Baccarani M. Zinzani PL, et al. Among authors: guardigni l. Lancet Oncol. 2008 Apr;9(4):352-8. doi: 10.1016/S1470-2045(08)70039-1. Epub 2008 Mar 14. Lancet Oncol. 2008. PMID: 18342572 Clinical Trial.
23 results